A new radiation beam, the π – meson beam, is being considered for radiotherapy of human neoplasms. It is clear that this beam has special attributes which make it useful in certain types of neoplasms. However, human experience is heavily based upon low LET beams, alterations of dose rate and treatment, planning to confine dose to required therapeutic volumes. The use of this new beam must be considered upon existing knowledge regarding the natural history of the neoplasms, and the expected biological properties of the pion beam. It is likely that revision of present fractionation schedules will be required but most likely the pions will be useful to treat the residual tumor core of a tumor reduced in size by prior external beam, low LET therapy.